Drugs / ISTH0036
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02406833 | Apr 2015 → Aug 2016 | open-angle glaucoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISTH0036 | “This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy).” NCT02406833 ↗ |
| Action | Inhibit | “an antisense oligonucleotide against TGF-β2” NCT02406833 ↗ |
| Modality | Antisense oligonucleotide | “a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide” NCT02406833 ↗ |
| Route | Intravitreal | “intravitreal injection” NCT02406833 ↗ |